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Kathryn B. Garber1,*One Man’s Junk Is Another Man’s Treasure
I could focus this entire column for the next few months
on recent publications from the ENCODE project. Suffice
it to say: there are many, they include a multitude of
data and interesting connections between data, and you
should probably at least take a peek at some of them! Just
as a sampling, take the meaty paper by Maurano et al.,
who tackle the puzzling association of noncoding SNPs
with many complex diseases and quantitative traits. Are
these just junk results from junk DNA? Several of the asso-
ciations are consistent enough that there is almost
certainly something to them. By piecing several large data-
sets together, this group implicates many of these SNPs in
the regulation of gene expression. To begin with, they
found a large amount of overlap between the location of
these SNPs and DNase I hypersensitivity sites, which
mark cis-regulatory elements, and most of these sites of
overlap correspond to transcription-factor-recognition
sequences. Tying all of this in with data from chromatin-
conformation capture experiments allowed the authors
to link these regulatory elements with putative target
genes, many of which are not the closest gene, at least in
the linear sense. Finally, they explore regulatory-gene
expression networks for related diseases. These networks
have the potential to increase our understanding of the
molecular pathogenesis of these diseases and thereby
turn what was once considered junk into genomic trea-
sure.
Maurano et al. (2012). Science 337, 1190–1195.Tick, Tock
Mutation happens. Typically, though, we only go hunting
for a mutation when we need it to explain a disease pheno-
type, so we are left with a limited understanding of the
background mutation rates in the human genome. With
high-throughput sequencing methods, we can theoreti-
cally detect all of the sequence changes that are present
in an individual regardless of phenotype. Through
comparisons with parental sequences, we can also tell
which of these changes were inherited and which were
new mutations, allowing us a better understanding of
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The America large scale; they assessed whole-genome sequences of
78 trios, and from these data they gleaned more precise
and genome-wide estimates of mutation rates than what
had been previously measured. Their results indicate
that, on average, each of us has about 60 de novo single-
nucleotide changes, although there is variation in the
exact number. The main driver of this variation is the age
of our fathers at the time we were conceived. With each
year that a father’s age increases, approximately two addi-
tional mutations can be found in his offspring. In contrast,
we each get approximately 15mutations that arise de novo
on our maternal allele, no matter how old our mother is
when we are conceived. This paternal association with
mutation rate isn’t as dramatic as the association of
maternal age with nondisjunction, but it does suggest
that there could be benefit if men listen to their biological
clocks, too, particularly given epidemiological evidence
for the association of paternal age with the risk of schizo-
phrenia and autism in a man’s offspring. On a population
scale, one can also use these data to speculate on the influ-
ence of changing demographics on the incidence of these
genetic disorders.
Kong et al. (2012). Nature 488, 471–475.Women’s Views on Abnormal Prenatal
Chromosomal Microarray Results
Trials comparing the information gleaned from karyotypes
and chromosomal microarrays for prenatal testing have
been completed, and publication is on the horizon.
Almost certainly, these will report increased detection of
pathogenic chromosomal abnormalities, but they will
also report increases in the detection of variation of uncer-
tain significance. Geneticists can argue the pluses and
minuses that come with this increased resolution, but it’s
important to keep in mind how these tests are perceived
by the people receiving the test results. Bernhardt et al.
recently interviewed 23 women who received positive or
uncertain results from prenatal chromosomal microarray
analysis, and their feelings are food for thought as the
use of this technology becomes more common in prenatal
testing.
Bernhardt et al. (2012). Genet. Med. Published online
September 6, 2012. http://dx.doi.org/10.1038/gim.2012.113.ta, GA 30322, USA
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A New Metabolic Form of Autism
Diets designed to manage autism seem to come in and out
of vogue among parents of affected children. The theory
behind the diets is that many children with autism also
report gastrointestinal issues. The diets are fairly generic;
some of them are gluten free, others include probiotics.
Butwhat if a specific diet could be tailored to theunderlying
causeof autism?This is thehope inwhat is likely tobe avery
rare type of autism caused by mutations in the branched
chain ketoacid dehydrogenase (BCKDH) kinase. Mutations
in genes for the subunits of the BCKDH complex are well
knownandcause the severemetabolic disordermaple syrup
urine disease, which is associated with elevated plasma
concentrations of the branched-chain amino acids leucine,
isoleucine, and valine. The opposite is true of these amino
acid levels in individuals in this study, who havemutations
in a negative regulator of the BCKDH complex, meaning it
is overactive. These abnormalities lead to epilepsy, autism,
and intellectual disability. A mouse model deficient for
Bckdh recapitulates these amino acid imbalances and has
a neurological phenotype that is responsive to dietary
supplementationwithbranchedchain aminoacids. Prelim-
inary studies in the patients suggest this dietary interven-
tionmight be promising in them too—at least, their amino
acid levels can be improved. We’ll have to wait to find out
whether this has an effect on the neuropsychological
phenotype; this study is planned once the researchers can
maximally stabilize the plasma branched-chain amino
acid levels with the diet.
Novarino et al. (2012). Science Express. Published
online September 6, 2012. http://dx.doi.org/10.1126/science.
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The point of genetic testing inmany cases is to explainwhy
an individualhas a certainphenotype and toget aprognosis
for the future. Although there is always going to be some
variability, one can be fairly confident in making predic-
tions based on certain classic genetic deletions. For other
copy-number changes, predictions are more difficult
because the same change can be found in persons with
a range of phenotypes, including no obvious phenotype
at all. Previously, Evan Eichler’s group proposed that
a second copy-number change might influence the pheno-
type associated with a primary copy-number event. They
recently explored this theory in a large study that assessed
secondary copy-number changes in more than 2,000 chil-
dren who each had one of 72 different primary copy-
number variants. Although some of these first hits are suffi-
cient to cause aphenotypewith little phenotypic variability
nomatter what else happens in the genome, their statistical
analysis supports the idea that there are other copy-number
changeswhose overall outcome ismodified by the presence
of independent secondary copy-number changes. This
second site variation influences the penetrance and expres-
sion of phenotypes attributed to the primary change. On
the one hand, one could speculate that the genes altered
by the independent copy-number events have somedepen-
dent functional interaction that could explain this finding.
On the other hand, the second hit could just be the knock-
out punch after the first randomblow.We’ll have towait for
more data before the decision is called on this one.
Girirajan et al. (2012). N. Engl. J. Med. Published
online September 14, 2012. http://dx.doi.org/10.1056/
NEJMoa1200395.This Month in Our Sister JournalsNF1 in the Driver’s Seat
Oneaimof cancer genomeanalyses is to uncovermutations
that are common in specific types of tumors. It is not always
straightforward to tease out which mutations kick started
the oncogenic process—in other words, the driver muta-
tions—and which are just along for the ride. To simplify
things, Wallace et al. used a mouse tumor model in the
hopes of identifying driver mutations for breast cancer.
This Chaos3 mouse has high amounts of genomic insta-
bility and commonly gets mammary tumors that have
gene expression profiles similar to those in human luminal
breast tumors, one of themost common types ofmammary
tumors inhumans.One recurrently deleted region found in
tumors in the Chaos3mice overlaps with a syntenic region
in humans that is commonly altered in breast cancers. Thekey gene in this region seems to be NF1, the gene that is
mutated in neurofibromatosis type 1. If mutation in NF1
is confirmed to be a common driver of human breast
tumors, it would have potential implications for the treat-
ment of breast cancer because loss of NF1 function alters
the sensitivity of tumor cells to certain drugs. For one,
tumor cell lines from the Chaos3mice are sensitive to drugs
that inhibit pathways relevant to Nf1. Others have shown
that breast tumors with lowerNF1 expression are less sensi-
tive to tamoxifen. This could impact a significant number
of women; an analysis of data from The Cancer Genome
Atlas suggests that almost 28% of human breast tumors
have mutations in or deletions of NF1.
Wallace et al. (2012). Genetics. Published online July 20,
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